Revolutionizing Medical Diagnostics: Innovations and Challenges

Carlsbad, CA (August 10, 2023) – RCE Technologies, Inc.

In the dynamic world of medical research, the quest for accurate diagnostics remains an ever-evolving endeavor. Dr. Frank Peacock, a distinguished figure in the medical community, shared his insights on groundbreaking projects during a recent AACC meeting. As the Vice Chair for Research at Baylor College of Medicine and a member of the Scientific Advisory Board of, his contributions are shaping the landscape of medical diagnosis and treatment.

One of the key focuses of Dr. Peacock’s work is centered around traumatic brain injuries, an area plagued by diagnostic uncertainties. In collaboration with experts, he co-edited a pivotal book on biomarkers and traumatic brain injuries, underscoring the pressing need for a definitive diagnostic approach. The challenge lies in the absence of a straightforward method for identifying this condition. Dr. Peacock highlighted the pivotal role of biomarkers, these molecular indicators offer an objective way to pinpoint brain injuries accurately. He also introduced the ongoing “HeadSmart Two” study, a pioneering effort aimed at identifying effective biomarkers for detecting brain injuries with precision.

Another remarkable endeavor spearheaded by Dr. Peacock revolves around cardiac health. He’s leading the development of a revolutionary point-of-care test, that can be leveraged to assess heart damage early. What sets this innovation apart is its non-invasive nature. Utilizing a wrist-strap device equipped with cutting-edge laser technology, real-time biomarker levels can be analyzed without the need for blood samples. The potential of this innovation expands beyond a single biomarker to encompass other biomarkers, opening doors to a new realm of real-time diagnostics.

However, the journey towards implementing such game-changing technologies is not without its hurdles. Dr. Peacock shed light on the stringent criteria set by the FDA in terms of accuracy and control. Ensuring that the data generated by these devices is reliable and consistent is paramount to their success. Additionally, the interpretation of continuous biomarker measurements such as Troponin demands the establishment of meaningful thresholds for diagnosis. Balancing innovation with reliability is the cornerstone of this endeavor.

Despite the transformative impact these innovations promise, they are not expected to be immediately available to the public. Dr. Peacock anticipates that a couple of years before the point-of-care cardiac assessment test and similar technologies become widely accessible in the market. This timeline accounts for the rigorous testing, fine-tuning, and regulatory processes essential for their safe and effective deployment.

In conclusion, Dr. Frank Peacock’s pioneering work exemplifies the leaps and bounds that medical diagnostics are taking. From redefining traumatic brain injury diagnosis through biomarkers to revolutionizing cardiac health monitoring with non-invasive technology, his efforts are reshaping the future of healthcare. While challenges persist, the potential to enhance patient care and outcomes is truly promising. The journey towards these advancements showcases the fusion of scientific innovation, medical expertise, and a relentless commitment to pushing the boundaries of what’s possible in modern medicine.

About, an innovative artificial intelligence (AI) based medical technology company launched in Carlsbad, Calif., in 2018, is dedicated to early heart attack detection. The company has revolutionized the monitoring of cardiac injury by introducing Infrasensor™, a non-invasive infrared-based wearable device. RCE’s proprietary transdermal approach, enhanced with deep learning techniques, analyzes and associates unique optical signatures with cardiac conditions in real-time. This AI-coupled transdermal approach enables the potential application of RCE’s technology in various emergency care settings and remote monitoring applications. Presently, RCE is engaged in clinical studies to optimize the Infrasensor for clinical use. Through ongoing clinical studies, the company hopes to soon secure FDA approval for its technology, opening the door to making it available for sale in the United States.